Streetbeat News

Products Services

CRL

Charles River Laboratories International, Inc. (NYSE:CRL) and PathoQuest SAS have published a study validating their Next Generation Sequencing (NGS) viral safety assay as a reliable alternative to animal testing methods. The study demonstrated that the NGS-based assay had a greater capability of detecting viral contaminants compared to in vivo assays. The results support the use of the evaluated NGS-based transcriptomic assay as a superior alternative to current in vivo testing methods and aligns with the proposed ICH Q5A(R2) guidelines which are anticipated to be finalized and implemented by the end of 2023.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 12:20 pm

VBIV

VBI Vaccines Inc. (NASDAQ:VBIV) and its partner Brii Biosciences announced positive interim results from a Phase 2 study of BRII-179 (VBI-2601), a treatment for chronic hepatitis B. The treatment, in combination with PEG-IFNα, showed increased HBsAg loss rate and a significantly increased seroconversion rate. The safety findings were similar to previous reports. In 2023, VBI and Brii Bio expanded their partnership to include an exclusive global license to develop and commercialize BRII-179 and an exclusive license for VBI's prophylactic 3-antigen adult HBV vaccine in the Asia Pacific region, excluding Japan.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 12:19 pm

TM

Toyota Motor Corporation (NYSE:TM) has launched a new version of its Century model in Japan, with plans for global customization. The new model, which is part of Toyota's focus on larger and luxury vehicles, is expected to launch in 2023. The Century model is a premium chauffeur-driven car, and the new version is expected to impact Toyota's brand image more than its bottom line.

Portfolio Pulse from Nabaparna Bhattacharya

September 06, 2023 | 12:18 pm

GRCL

Gracell Biotechnologies Inc. (NASDAQ:GRCL) will present updated results from the ongoing Phase 1 trial in China evaluating FasTCAR-enabled GC012F in high-risk patients with newly diagnosed multiple myeloma at the 20th International Myeloma Society Annual Meeting. The company believes GC012F, with its impressive safety profile and innovative design, is a compelling candidate to address the unmet needs for this patient population.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 12:18 pm

VCYT

Veracyte and Gustave Roussy have announced a collaboration aimed at helping biopharmaceutical companies accelerate the development of novel cancer therapies. The partnership will leverage Veracyte's genomic testing capabilities to identify potential therapeutic targets.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 12:16 pm

GNSS

Genasys (NASDAQ:GNSS), a global leader in protective communications solutions, has announced that the City of Boston has deployed its Genasys Protect platform. The platform will be used for mass notifications, providing real-time critical collaboration between all departments and the community. The system will allow the city to send emergency and non-emergency notifications to specific geographic areas, citizen lists, and staff through single or multiple communication channels.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 12:14 pm

BNGO

Bionano Genomics, Inc. (NASDAQ:BNGO) announced a publication from the German Cancer Consortium showing the utility of optical genome mapping (OGM) and whole-exome sequencing (WES) in understanding pediatric B-cell precursor acute lymphoblastic leukemia. The research found that OGM and WES may provide novel insights into disease development and progression. The findings may result in meaningful revisions to various risk classifications and disease stratifications, which are known to affect outcomes.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 12:14 pm

BAND

GOOG

GOOGL

Bandwidth has partnered with Google and Cognigy to launch AIBridge, a new product aimed at enhancing customer experience through AI technology.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 12:13 pm

HOTH

Hoth Therapeutics has completed its analysis of the data from its Phase 1B clinical trial of Biolexa as a therapeutic for atopic dermatitis. The results show that 78% of patients reported that their overall health had improved since starting Biolexa.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 12:13 pm

TEVA

Teva Pharmaceuticals will present 16 data presentations at the Psych Congress 2023, including data for AUSTEDO, AUSTEDO XR, UZEDY, TV-44749, and AJOVY. The presentations will highlight real-world effectiveness and adherence of AUSTEDO, safety data for UZEDY, and results from the RISE and SHINE studies. Teva will also host a symposium to discuss the DECIDE study, which surveyed clinician perspectives on the use of long-acting injectable antipsychotics.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 12:10 pm